TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to persistent modified CTCAE grade ≤ 1 ir-colitis/diarrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Response rates to platelet-raising therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Primary change in the Physician Global Assessment (PGA)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maternal cardiac function (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Neonatal cardiac function (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with non-serious Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Fridericia's corrected QT interval (QTcF) (ΔQTcF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hamilton Rating Scale Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Presence and reaction to memory and behavior problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean Renin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Capsular contracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants with treatment-related adverse events (AEs) of grade 3 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: % time frozen during a personalized gait trajectory
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical complete response (cCR) at 10 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of percent-predicted airway resistance at 5Hz (%R5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percentage reduction in opioid consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in gastritis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic accuracy of detecting coronary atherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Recurrence of dental black stain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VAS Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in the percentage of time in range 70-180 mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of Successfully Completed Treatments
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Changes in maximal isometric handgrip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 6-m gait speed test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Time Up and Go test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Sit and Stand Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: analgesia success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in choroidal tumor thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in choroidal tumor largest basal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemispheric dominance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of eosinophils
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Fugl Meyer Assessment (upper extremity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adverse events associated with EPE
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy as assessed by validated pharyngeal dysphagia questionnaire EAT-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of EPE on swallowing via effects on pyriform sinus and vallecular residue height and width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of EPE on swallowing via effects on routinely measured markers of deglutition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of uterine fibroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in circulating pro-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safety and tolerability of IGM-7354
Endpoint domain: Adverse events/effects
Primary endpoint: BARC classification bleeding ≥3
Endpoint domain: Adverse events/effects
Primary endpoint: Hemogram recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Scientific Assessment Scale of Skin Quality (SASSQ) Rating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Inflammatory Rasch-built Overall Disability Scale (I-RODS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absence of device or procedure related major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in TR grade from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG-waveform amplitude & timing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMG co-activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported emotion ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Whole brain BOLD signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pediatric Respiratory Assessment Measure (PRAM) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Suprasternal indrawing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Scalene retractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Air entry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change from baseline Oxygen saturation on room air
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: VAS pain (0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to become asymptomatic for COVID-19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HFpEF incidence
Endpoint domain: Mortality/survival
Primary endpoint: APOs incidence
Endpoint domain: Mortality/survival
Primary endpoint: Faecal microbiome composition analyses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood pressure during surgery in mmHg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart rate (beats/minute)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative pain using FLACC score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent change in body weight from baseline to week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: clinically significant weight loss after discontinuing tirzepatide therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of participants discontinuing treatment secondary to treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Endothelial function, % flow-mediated dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Serum LDL cholesterol, mg/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to substantial alleviation of COVID-19 symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Therapeutic Oxygen-Free Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral Clearance by Nasopharyngeal Swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in 7-day average composite score of 3 cardinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Awareness with Paralysis
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants With Premature Discontinuation of Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Laboratory Abnormality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nonattendance rate of colonoscopy appointment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Bias for oral breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bias for nasal breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of perioperative RBC transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pressure pain threshold (PPT) in the evaluated muscles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported pain intensity: Numeric Pain Rating Scale (NPRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-perceived quality of life: A36 Haemophilia-QoL test
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of Participants with Viral Control Without ART Restart
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of wrist power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge of Vital Pulp Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: five day fasting glucose average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: five-day first hour postprandial glucose average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: five-day second hour postprandial glucose average
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in the number of episodes of sustained VT/VF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in arrhythmia burden quantified by Holter ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Readmission for heart failure or ER visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Total usage of propofol and fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: IBM Functional Rating Scale (IBMFRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma β-hydroxybutyrate (βHB) kinetics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial de novo lipogenesis (DNL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plaque deposits (Plaque index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival health (Gingival index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of appliances in terms of survival time
Endpoint domain: Mortality/survival
Primary endpoint: Anxiety levels measured by the Hamilton Anxiety Rating Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: One year progression-free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: Severity of treatment emergent adverse events as measured by CTCAE v 5.0
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: COVID-19 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC from time 0 extrapolated to infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from time 0 to 24 hours (AUC0-24)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech reception threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in liver stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary tract function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of urinary dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of postpartum women requiring epidural blood patch
Endpoint domain: Adverse events/effects
Primary endpoint: ANGPTL-4 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantitative Myasthenia Gravis Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myasthenia Gravis Composite
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myasthenia Gravis Quality of Life-15
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in VHI Questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Vaginal Health Index (VHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Vaginal Maturation Index (VMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Unanticipated Adverse Device Effect (UADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in HAMD-17
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MPQ
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in PASS
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood inflammation biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CSF inflammation biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Voxel-wise, regional and total brain TSPO VT/fP measured with 11C-ER176 PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SEP measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Joint amplitudes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in heart rate variability immediately after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in heart rate variability 15 minutes after the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants with at least 1-point improvement on MLFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subject-reported depressive symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Subject-reported anxiety symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Clinical diagnosis of depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in knee pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychiatric comorbidities in children and adolescents with ADHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidences of Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Rate Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Rating
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Percentage of participants with solicited injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with solicited systemic reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Composite of cardiac death, valve thrombosis, valve-related thromboembolic event, major bleeding, and clinically-relevant non-major bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants with specific Adverse outcome in patients with UC with exposition of systemic glucocorticoids
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with any Adverse outcome in patients with UC with exposition of systemic glucocorticoids
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with specific Adverse outcome in participants with UC without exposition of systemic glucocorticoids
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants with any Adverse outcome in participants with UC without exposition of systemic glucocorticoids
Endpoint domain: Adverse events/effects
Primary endpoint: Quantitative bacterial count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Compliance with ERACS guidelines
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Bone toughness (Fragility Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pulmonary auscultation recordings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Behavioral performance (Accuracy as fraction of correct responses)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurophysiological activity (single-neuron activity in spikes/second)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Missed scanning rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short form 36 quality of life questionnaire (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: knowledge on occupational safety and health
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: attitude on occupational safety and health
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: practice on occupational safety and health
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Microscopy positive P. vivax recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Consolidation of fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of post traumatic stress disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Blood insulin concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Level of Translocator Protein (TSPO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Microhemorrhages
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Cerebral Blood Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Prolactin value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Grade 3 or 4 sign/symptom, laboratory abnormality, or death related to the vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: 2 consecutive viral loads of 400 copies/ml or more while receiving HAART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 2 consecutive absolute CD4 cell counts of 250 cells/mm3 or more while receiving HAART
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 2 consecutive CD4 cell counts more than 50% below the baseline CD4 cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: sensitivity of imaging modalities in nodal-status assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of melasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Fatigue Inventory Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Hamilton Depression Scale-24
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Combined Incidence of HPV-related External Genital and Intra-anal 12-month Persistent Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes